IRIS
IEZZI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 944
EU - Europa 558
AS - Asia 243
SA - Sud America 4
Totale 1.749
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 944
CN - Cina 132
IE - Irlanda 127
SE - Svezia 103
IT - Italia 98
UA - Ucraina 72
FR - Francia 68
TR - Turchia 65
DE - Germania 37
GB - Regno Unito 32
IN - India 20
VN - Vietnam 20
AT - Austria 7
FI - Finlandia 4
BE - Belgio 3
HK - Hong Kong 2
PY - Paraguay 2
RO - Romania 2
SG - Singapore 2
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
JP - Giappone 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 1.749
Salva come PNG Salva come JPEG
Città #
Chandler 237
Jacksonville 127
Dublin 126
Dearborn 90
Ashburn 56
Houston 55
Princeton 52
Izmir 39
Nanjing 39
Wilmington 28
Altamura 26
Chieti 26
Beijing 22
Ann Arbor 21
Dong Ket 20
Boardman 18
Southend 16
Cambridge 13
Kunming 12
Nanchang 10
Washington 10
Los Angeles 9
New York 9
Shenyang 8
Jiaxing 7
Norwalk 7
Vienna 7
Tianjin 6
Hebei 5
Pescara 5
Hefei 4
London 4
Woodbridge 4
Brussels 3
Falls Church 3
Hangzhou 3
Pune 3
Savigliano 3
Tappahannock 3
Asunción 2
Cerveteri 2
Changsha 2
Hong Kong 2
Leicester 2
Loreto Aprutino 2
Palagiano 2
Santa Clara 2
Zhengzhou 2
Ameno 1
Amsterdam 1
Apo 1
Brdo 1
Campobasso 1
Castano Primo 1
Changchun 1
Chicago 1
Colleferro 1
Copenhagen 1
Dallas 1
Edinburgh 1
Frankfurt am Main 1
Grevenbroich 1
Guangzhou 1
Gunzenhausen 1
Harbin 1
Hunedoara 1
Jinan 1
Jinhua 1
Lanciano 1
Medford 1
Milan 1
Nanning 1
Ningbo 1
Pieve 1
Redwood City 1
Rome 1
Seattle 1
Shaoxing 1
Spoltore 1
Stanford 1
Stockholm 1
São Paulo 1
Taizhou 1
Tashkent 1
Tokyo 1
Vilnius 1
Wenzhou 1
Totale 1.193
Salva come PNG Salva come JPEG
Nome #
Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis 103
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 91
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 87
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 83
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 82
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 80
null 79
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 78
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer 77
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 77
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 77
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study 74
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 73
Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience 73
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 72
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 72
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 72
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 71
Triple positive early breast cancer in the pre- and post Trastuzumab eras: a subgroup analysis of a multicenter retrospective study. 68
Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study. 67
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 66
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 66
Fulvestrant (FUL) 500 milligrams as endocrine therapy (ET) for hormone sensitive advanced breast cancer patients (pts). The Ful500 prospective observational trial 61
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 57
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 54
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 49
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 17
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 11
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 1
Totale 1.938
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201961 0 0 0 0 0 0 0 0 0 0 6 55
2019/2020560 128 20 21 30 65 57 63 29 53 52 37 5
2020/2021139 20 1 31 2 7 30 3 4 5 5 3 28
2021/2022142 0 6 0 33 6 4 6 8 9 4 15 51
2022/2023561 38 75 38 77 48 100 22 55 69 7 21 11
2023/2024250 31 13 17 11 19 99 38 5 6 11 0 0
Totale 1.938